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Abstract
In late-stage metastatic colorectal cancer, difficult treatment decisions should incorporate a thorough evaluation of the
patient’s general condition and subject for shared decision making. Assessment of the individual patients’ prognosis is valu-
able in this setting. The aim was to analyze the prognostic value of plasma levels of total cell-free DNA, carcinoembryonic
antigen and C-reactive protein in 97 heavily pretreated patients with metastatic colorectal cancer. Patients received irino-
tecan, cetuximab, and everolimus in a phase-2 clinical trial (clinical trials.gov NCT01387880). Plasma samples were used
for DNA purification and quantification of total cell-free DNA by droplet digital polymerase chain reaction. Serum carci-
noembryonic antigen and C-reactive protein were analyzed by routine methods. Clinical endpoints were overall survival
and progression-free survival. A total of 82 patients had blood samples available for quantification of total cell-free DNA.
Patients with pre-treatment cell-free DNA levels higher than the median total cell-free DNA (9800 alleles per milliliter
plasma) had a significantly shorter overall survival of 4.3months (95% confidence interval: 3.6–5.8) compared to patients
with cell-free DNA levels below the median with an overall survival of 11.3months (95% confidence interval: 8.0–14.8,
p\ 0.0001). When using the upper normal limit from a previously analyzed normal control group, the median overall sur-
vival was 11.3 (95% confidence interval: 7.3–14.8) and 4.3 (95% confidence interval: 3.7–6.1) months, respectively
(p\ 0.0001). Serum carcinoembryonic antigen and C-reactive protein had similar prognostic value with short overall sur-
vival and progression-free survival in patients with elevated levels compared to those within normal range. A high-risk
profile of elevated cell-free DNA, carcinoembryonic antigen, and C-reactive protein was described, but in combined Cox
regression multivariate analysis, only total cell-free DNA preserved a strong prognostic value. In conclusion, total cell-free
DNA in plasma, carcinoembryonic antigen, and C-reactive protein could all contribute to assessment of patients’ prog-
nosis and potentially aid in clinical decision making in patients with metastatic colorectal cancer.
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Introduction
Evaluation of patients’ general condition and prognosis
is essential in daily clinical decision making, as also
emphasized in the latest update of the European
Society of Medical Oncology (ESMO) consensus guide-
lines for treatment of metastatic colorectal cancer
(mCRC).1 The panel of available standard drugs for
mCRC includes fluoropyrimidine, irinotecan, and oxa-
liplatin in addition to biological agents, and the median
overall survival (OS) reported from clinical trials has
now exceeded 2 years.2 More recently, the role of
immunotherapy is being intensively investigated in
mCRC, but positive results have so far been limited to
small subgroups of microsatellite instability-high (MSI-
H) patients.3 The biological behavior of this disease is
still far from understood regarding the role of immuno-
genic reactions and inflammatory processes.
Consequently, patients with chemotherapy refrac-
tory mCRC still have limited effective treatment
options, and palliative late-line therapy should be con-
fined to those with the highest chance of benefit and
carefully balanced against risk of potential adverse
events. There is increasing awareness of the possibilities
for shared decision making between patients and clini-
cians in these difficult situations,4,5 and assessment of
the individual patient’s prognosis is essential to bring as
exact knowledge to the discussion as needed. Reliable
prognostic biomarkers could potentially help in selec-
tion of patients and contribute to avoid unnecessary
harmful effect without clinical benefit. Unfortunately,
there are only limited validated biomarkers for out-
come in patients with mCRC.
The only established biomarker in patients with
CRC is carcinoembryonic antigen (CEA), which is cur-
rently debated due to its unspecific nature, but in gen-
eral elevated serum levels of CEA are associated with
poor prognosis. There is increasing focus on the role of
immune-inflammatory mechanisms in CRC, including
C-reactive protein (CRP) and interleukin-6 (IL-6) mea-
surement as recently described in a retrospective
Nordic analysis in the first-line setting of patients with
mCRC.6 High serum levels of CRP, which is easily
measured and used as standard analysis, implied a
shorter progression-free survival (PFS) and OS, empha-
sizing the role of systemic inflammatory processes in
this disease. It is, however, generally known that CRP
elevations occur in many pathological conditions, and
coexisting conditions precluding disease-specific dete-
rioration cannot be excluded on this basis.
In contrast, we have recently reported that circulat-
ing free DNA, that is, cell-free DNA (cfDNA) mea-
sured in the plasma, is significantly increased in patients
with CRC compared to healthy controls, with only
limited variations related to non-cancerous co-morbid-
ities.7 A meta-analysis indicated a strong prognostic
value of the total cfDNA plasma levels in nine cohorts
of patients with mCRC.8 In a recent report, we demon-
strated increasing level of total cfDNA concentration
with higher stage of rectal cancer9 but have been unable
to confirm a direct correlation to tumor volume in the
metastatic setting, when analyzed in relation to positron
emission tomography (PET)/computed tomography
(CT) volume parameters.10,11 These observations sug-
gest that the clinical influence of cfDNA is not only a
mirror of disease volume, rather a more complex biolo-
gical picture in mCRC, strongly correlated to outcome.
Further knowledge into the biological mechanisms is
needed.
A combination of markers representing tumor
biology and systemic inflammatory responses is conse-
quently of major scientific interest and the focus of this
study. We aimed to analyze the prognostic value of
total cfDNA quantification and elevated serum levels
of CEA and CRP in a Danish cohort of heavily pre-
treated patients with mCRC.
Materials and methods
Patients
A total of 115 patients with chemotherapy refractory
mCRC were included in a phase II study investigating
the efficacy of irinotecan (180mg/m2), cetuximab
(500mg/m2), and p.o. everolimus (2.5, 5.0, 7.5 or maxi-
mal dose of 10mg; daily for 14 days) in third or fourth
line. All patients were required to have histological or
cytological confirmed locally advanced or metastatic
adenocarcinoma of colon or rectum not eligible for
local treatment. Patients were required to have at least
one measurable lesion according to RECIST 1.1. Prior
therapy with 5-fluorouracil (5FU), irinotecan, cetuxi-
mab, and oxaliplatin was required unless oxaliplatin
was contraindicated or the patients did not tolerate the
compound. Other criteria included age ø 18 years, a
life expectancy of more than 3months, a World Health
Organization (WHO) performance status (PS) ł 2,
KRAS wild type, adequate bone marrow with an abso-
lute neutrophil count (ANC) ø 1.5 3 109L21 and pla-
telet count ø 100 3 109L21, and normal hepatic
function with a bilirubin ł 1.5 upper normal limit
(UNL) and aspartate aminotransferase and alanine
transaminase ł 5 UNL, unless liver metastases were
present. Exclusion criteria included pregnancy and lac-
tation, known hypersensitivity to everolimus or other
rapamycin, any severe and/or uncontrolled medical
condition, uncontrolled diabetes as defined by fasting
glucose above 1.5 3 UNL, serious liver disease, or a
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history of uncontrolled gastrointestinal bleeding.
Written informed consent was obtained from all
patients, and the study (http://www.clinicaltrials.gov,
number NCT01387880) was approved by the Regional
Scientific Ethics Committee VEK (20091116). The
patients were included at three Danish hospitals from
January 2010 to September 2011, and the primary
results of this trial will be presented elsewhere. All
patients died during follow-up and the median follow-
up was 0.6 years (range: 7.00 days–3.8 years). Patients
had blood samples drawn prior to and during therapy
for translational research.
Sampling
Blood samples from 97 patients were used for this
study, including samples drawn at four different time
points: before the first cycle of chemotherapy, before
the second cycle, before the second last cycle, and
immediately prior to the time of radiologically verified
progression. The baseline samples were used for prog-
nostic evaluation of cfDNA, CEA, and CRP.
Plasma was obtained from a 3.5mL blood sample
collected in citrate tubes and centrifuged (2300g for
10min at 4C) within 2 h of collection and then stored
in plasma aliquots at 280C until analysis.
Cell-free DNA was extracted from 1 to 2mL plasma
using the QIAamp Circulating Nucleic Acid Kit
(Qiagen) according to the manufacturer’s instructions.
A multiplex droplet digital polymerase chain reaction
(ddPCR) reaction measuring Beta-2 Microglobulin
(B2M) and the lymphocyte-contamination control pri-
mary biliary cirrhosis (PBC)12,13 was set up on the
QX200 droplet digital PCR system (Bio-Rad) and per-
formed on all samples. B2M was used as an estimate of
total cfDNA concentration, while PBC was used to
identify samples with lymphocyte DNA contamination.
Contamination was calculated as the ratio between
PBC and B2M. Samples with PBC. 0.01% were
excluded from further analysis. Reactions consisted of
5mL sample, 1mL of each primer-probe mix, and
10mL 2 3 ddPCR Supermix for probes (Bio-Rad).9
Primers and probes are previously published11 and
shown in Supplementary Table 1. The cycling steps for
the ddPCR were as follows: 95C for 10min, 40 cycles
of 94C for 30 s, and 60C for 1min, and finally 98C
for 10min. The ddPCR reactions were performed
according to manufacturer’s recommendations, and all
runs included positive and negative controls used for
setting threshold.
The resulting number of copies per microliter reac-
tion volume was used to estimate the number of copies
per milliliter plasma. Copies per microliter reaction vol-
ume were multiplied by the total reaction volume
(22mL), divided by the sample input volume (5mL),
multiplied by the cfDNA elution volume (100mL), and
finally divided by the total input plasma volume (1–
2mL). Analysis was performed at Department of
Clinical Biochemistry, Aarhus University Hospital,
Denmark.
As part of routine management, serum CEA and
CRP were measured at baseline. CEA was analyzed
using the Siemens Healthcare Diagnostics ADVIA
Centaur CEA analysis, a two-site sandwich direct che-
miluminometric assay. CRP was measured by a high-
sensitivity turbidimetric assay (Dako). The UNL for
CEA (5ng/mL) and CRP (10mg/L) were used for cut-
off in survival analysis.
Statistics
Correlations between patient characteristics and
cfDNA were analyzed by the Wilcoxon rank sum test
or cross-tabulation when appropriate. Analysis of var-
iance (ANOVA) was used to describe the dynamics of
cfDNA levels during therapy, and receiver operating
characteristic (ROC) curve was used to illustrate the
value of differences in plasma cfDNA levels from a pre-
viously analyzed normal cohort.14 OS was calculated
from the time of inclusion until the date of death from
any cause, and PFS was calculated from the time of
inclusion until death or progression of mCRC. Survival
data were analyzed by Kaplan–Meier method, and dif-
ferences between the groups were estimated by the log-
rank test. The independent effect of different variables
was investigated in a multivariate Cox regression analy-
sis. Both known prognostic variables and the variables
of interest in the study were included in the model.
Two-sided p values \0.05 were considered as signifi-
cant. All statistics were carried out in the NCSS statisti-
cal software (NCSS Statistical Software; version
07.1.15, 2009).
Results
The results of the primary clinical trial will be published
separately. A total of 97 patients had plasma samples
available for DNA quantification. Total cfDNA quan-
tification was possible in all samples, but contamina-
tion from normal lymphocytes was detected in 15 cases
(PB levels .0.01%) leaving a total of 82 samples avail-
able for correlation to clinical data. The median level of
B2M alleles per milliliter plasma was 9800 copies/mL
(range 1700–255,600), comparable to previously pub-
lished studies.9–12,15
Cell-free DNA levels and relation to general biological
parameters
Analyses of the median plasma levels of cfDNA reveal
significantly higher plasma cfDNA in patients with
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poor PS. Baseline plasma cfDNA levels were also ana-
lyzed in relation to standard biological blood para-
meters including hemoglobin (HGB), platelets, absolute
neutrophil count (ANC), white blood cell (WBC)
count, bilirubin, and lactate dehydrogenase (LDH).
Results of correlation analysis revealed a primarily sig-
nificant positive correlation between cfDNA and LDH
and CEA and CRP (plots/data not shown, p\ 0.05).
Plasma cfDNA and serum CEA and CRP levels in rela-
tion to the PS of the patients are shown in Figure 1,
and an association with PS by all three parameters is
also shown in Figure 1.
Cell-free DNA dynamics during therapy
The median plasma levels of cfDNA significantly
decreased during the first cycles of therapy and showed
increasing levels toward time of progression, when ana-
lyzed by ANOVA test. The median level increased from
6200 alleles per milliliter (95% confidence interval (CI):
4600–9000) to 9300 (95% CI: 7800–13,700) at the time
of disease progression as shown in Figure 2. Although
dynamics seem to mirror biology, analysis of the rela-
tive early changes from baseline and before the second
cycle did not provide supplementary prognostic infor-
mation to the observation described in the following.
Baseline marker levels and clinical outcome
The baseline plasma cfDNA level was significantly
higher in patients with a poor outcome from treatment.
To analyze the prognostic value of cfDNA, quartiles
were used for log rank testing and revealed that there
was a significantly longer PFS and OS in patients with
low levels of cfDNA and decreasing median survival
with increasing number of alleles. When dividing
patients into four groups based on quartiles (Q) of base-
line cfDNA levels, the median OS was 13.1months
(8.6–16.6; lowest Q1), 7.3months (5.5–10.4; Q2),
5.6months (4.3–7.0; Q3), and 2.6months (2.0–6.1; high-
est Q4), respectively (p=0.0007). Notably, patients
with levels above the 75% quartile had a median OS of
Figure 1. Box and whisker plots of the three biomarker levels in relation to patient ECOG performance status. Figure 1 depicts
Box and whisker plots with 25%, 50%, and 75% percentiles and upper and lower adjacent values and outliers (dots). Horizontally, the
one group of patients according to performance status 0–2; vertically, the (a) cfDNA, (b) CEA and (c) CRP concentrations.
Figure 2. Dynamics of total cfDNA during therapy by ANOVA
analysis. Figure 2 depicts the total cfDNA concentration
measures as B2M alleles per milliliter plasma on the vertical axis.
Time points of blood sampling 1–4 are marked on the horizontal
axis (1—baseline, prior to initiation of treatment, 2—prior to
the second cycle of treatment, 3—second last sample drawn
(2weeks prior to radiologically verified progression), and 4—
time point of progression).
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2.6months compared to 8.0months in the group of
patients below the 75% quartile. The hazard ratio (HR)
was 2.41 (95% CI: 1.21–4.79, p\ 0.0005) indicating a
strong detrimental effect on survival in this group of
patients.
Patients with pre-treatment levels higher than the
median total cfDNA (9800 alleles per milliliter plasma)
had a significantly shorter median OS of 4.3months
(95% CI: 3.6–5.8) compared to patients with levels
below the median, with 11.3months (95% CI: 8.0–14.8;
HR: 2.75 (95% CI: 1.67–4.55), p\ 0.0001). When
using a pre-defined cut-off (9500 alleles per milliliter
plasma) based on the UNL from a previously analyzed
normal control group,8 the HR for OS was 2.54 (95%
CI: 1.58–4.08, p\ 0.0001; Figure 3). The same applied
to PFS with longer median interval in favor of patients
with the lowest plasma cfDNA levels (median PFS of
4.0months (95% CI: 2.9–4.7), compared to 1.9months
(1.7–2.6; HR: 2.11 (95% CI: 1.28–3.49), p=0.0009)),
as shown in Figure 4.
Univariate survival analysis of CEA showed that
high serum CEA (i.e. above the UNL of 5 ng/mL) was
associated with poor prognosis. The OS HR was 2.18
(1.27–3.75, p=0.03) with the median OS of
12.4months (95% CI: 8.3–39.1) in patients with normal
CEA compared to 7.0months (95% CI: 5.6–8.0) in
patients with elevated serum CEA levels. Significantly
longer PFS was also found in patients with normal
CEA levels (data not shown). However, only eight
patients showed normal levels of CEA at the beginning
of therapy.
Similarly, univariate survival analysis of CRP
showed that high serum CRP (i.e. above the UNL of
10mg/L) was associated with poor prognosis. The
approximately 25% of patients with normal serum lev-
els of CRP at baseline had significantly longer PFS
(median PFS of 4.2months (95% CI: 3.9–5.2months);
HR=2.02, 95% CI: 2.07–8.51, p=0.002) and longer
OS (median OS of 11.3months (95% CI: 7.5–
16.2months; HR=2.0, 95% CI: 1.34–3.01,
p=0.0012)) compared to those with higher CRP levels
(median PFS of 2.5months (95% CI 2.0–3.6months);
median OS of 5.5months (95% CI 4.2–6.9months)).
The corresponding Kaplan–Meier curves for PFS and
OS are presented in Figure 3.
Combining the three parameters identified a group
with triple elevated levels of cfDNA, CEA, and CRP
and a median PFS HR of 2.62 (95% CI: 1.46–4.70,
p\ 0.00001) and median PFS of 4.0months (2.9–4.7)
and 1.8months (1.6–2.0) in low- and high-risk groups,
respectively. The HR for OS in the high-risk group was
2.93 (1.71–5.02, p\ 0.0001) and median OS was
4.0months (2.9–5.6) in the patients with high levels
compared to 10.3months (95% CI: 8.0–12.4) in patients
with low levels of cfDNA, CEA, and CRP. The corre-
sponding Kaplan–Meier curves for PFS and OS are
shown in Figure 3. However, when building a multivari-
ate analysis including PS, CEA, CRP, and cfDNA, only
elevated total cfDNA plasma levels showed indepen-
dent prognostic value in this study, as demonstrated in
Table 1.
Discussion
Clinical decision making in patients with advanced
incurable metastatic CRC should include patients’ pre-
ferences and detailed discussion of the potential pallia-
tive options.4,5 Since late-stage disease often implies an
inevitable deterioration of health, a nuanced evaluation
of patients’ general condition as well as prognosis are
important aspects to consider in order to provide the
best care for the patient. These aspects can be valuable
tools for both patient and treating physician during
shared decision making regarding the relevance of sys-
temic therapy.
Inflammatory processes and cancer are closely
related, and it is well described that systemic inflamma-
tion can cause tumor progression and high
Table 1. Univariate and multivariate analyses.
Variables Univariate Log-rank tests Multivariate Cox regression analysis
p value OS
OS PFS Hazard ratio (95% CI) p
cfDNA UNL \0.001 \0.001 1.48 (1.10–1.99) 0.01
CEA UNL 0.02 .0.05 1.10 (0.59–2.06) 0.77
CRP UNL 0.0014 0.002 1.25 (0.92–1.70) 0.14
Performance status (0/1, 0/2) 0.0085 .0.05
.0.05
1.22 (0.79–1.88)
1.21 (0.66–2.24)
0.37
0.54
Gender (male/female) .0.05 .0.05 0.96 (0.72–1.27) 0.76
Tumor KRAS status (wt/mutated) .0.05 .0.05 1.06 (0.78–1.43) 0.71
OS: overall survival; PFS: progression-free survival; CRP: C-reactive protein; UNL: upper normal limit; CI: confidence interval; CEA:
carcinoembryonic antigen; cfDNA: cell-free DNA.
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inflammatory activity is associated with poor prognosis
in various cancer settings. These aspects are increas-
ingly subject for clinical investigations by, for example,
the addition of anti-inflammatory mediators to
systemic treatment of patients with CRC as recently
reviewed and use of nonsteroidal anti-inflammatory
drugs (NSAID)/aspirin to lower the risk of CRC devel-
opment.16,17 However, tumors with high antigenic
Figure 3. Kaplan-Meier plots of survival according to the different markers: (a) OS in patients with levels of cfDNA in quartiles (N
= 20, 21, 21, and 22, respectively, p = 0.0007). Highest quartile left, lowest quartile right. (b) OS in patients with levels of cfDNA
above (n = 42, blue line) and below (n = 39, red line) the UNL (HR = 2.54, p\ 0.0001). (c) PFS in patients with levels of cfDNA
above (n = 35, blue) and below (n = 34, red) the UNL (HR = 2.11, p = 0.0009). (d) OS in patients with levels of CEA above (n = 84,
blue) and below (n = 8, red) the UNL (HR = 2.18, p = 0.02). (e) OS in patients with levels of CRP above (n = 70, blue) and below (n
= 26, red) the UNL (HR = 2.0, p = 0.0014). (f) OS in high- (n = 42, blue) and low-risk (n = 50, red) patients stratified by triple
marker analysis (HR = 2.93, p\ 0.0001).
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properties, that is, the MSI-H tumors with a high fre-
quency of microsatellite instability, are characterized
with a substantial local immune response and inflam-
matory processes and hold a better prognosis and as
more recently demonstrated, potential sensitivity to
immunotherapy.3 The interaction between immune
responses, inflammation, and tumor activity is thus far
from fully understood, but with emerging data and new
targets for immunotherapy, a deeper as well as more
direct clinical understanding is urgently needed.
Consequently, the search for predictive and prognostic
biomarkers in patients with mCRC should include not
only tumor-specific mechanisms but also take into con-
sideration the importance of the microenvironment and
inflammatory processes.
Since tumor-promoting inflammation is an emerging
cancer, hallmark inflammatory biomarkers are of special
interest in the search for new valuable prognostic bio-
markers in patients with CRC.18,19 This study has there-
fore investigated three parameters with biological
information related to CRC and systemic inflammation
and confirmed a strong prognostic value of CEA, CRP,
and total cfDNA, with an independent superior prog-
nostic influence of the total cfDNA. To the best of our
knowledge, no similar investigations have been reported.
Results have demonstrated a clear relation between all
three parameters and patients’ general condition, as
described by Eastern Cooperative Oncology Group
(ECOG) PS, which in itself hold prognostic information.
In addition, we reported a clear correlation between the
quantitative cfDNA concentration and the acute phase
reactant, but also demonstrated that the cfDNA mea-
surement hold a superior independent prognostic value
compared to the latter. This observation supplements
our previous data of a strong prognostic value8 with
new biological observations and could help assist in clin-
ical decision making in heavily pretreated patients with
mCRC. In general, patients with low levels of cfDNA
and normal inflammatory parameters seem to benefit
more from systemic treatment, whereas those with
higher levels show early progression and more rapid
deterioration. Risk assessment for patients with high lev-
els of all three parameters has revealed an HR for death
of 2.93 and an median survival difference of more than
6months in patients with low levels of all markers.
Whether an observed high-risk condition including poor
PS and high levels of the prognostic biomarkers is
potentially reversible upon effective systemic therapy
and/or addition of anti-inflammatory mediators could
be subject for future clinical studies.
In conclusion, at this point, we have identified poten-
tially interlinked strong prognostic biomarkers in
patients with mCRC, as well as demonstrated the strong
independent influence of total cfDNA levels, the clinical
implication of which should be further investigated.
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